Little Green Pharma Ltd
ASX:LGP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.5), the stock would be worth AU$0.14 (49% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | AU$0.09 |
0%
|
| 3-Year Average | 0.5 | AU$0.14 |
+49%
|
| 5-Year Average | 0.6 | AU$0.17 |
+84%
|
| Industry Average | 5.8 | AU$1.64 |
+1 646%
|
| Country Average | 2.7 | AU$0.75 |
+700%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Little Green Pharma Ltd
ASX:LGP
|
30.6m AUD | 0.3 | 4.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 31.4 | 40.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6.7 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.9 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 5.9 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 5.3 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 6 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 1.8 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 6.4 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.3 |
| Max | 2 199.4 |
Other Multiples
Little Green Pharma Ltd
Glance View
Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. The company is headquartered in Perth, Western Australia. The company went IPO on 2020-02-20. The Company’s products includes LGP Classic range and LGP Flower range. Its LGP Classic range includes tetrahydrocannabinol (THC) and cannabidiol (CBD) ratios presented in an oil formulation. Its LGP Flower range is grown and manufactured in the Southwest of Western Australia and supplied as dried medicinal cannabis whole flowers. The firm supplies medical-grade cannabis products to Australian, European and overseas markets. The company is also engaged in promoting education and outreach programs.
